Tools for Enabling Process Analytical Technology Applications in Biotechnology - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Tools for Enabling Process Analytical Technology Applications in Biotechnology
The success of process analytical technology (PAT), a recent initiative by FDA, depends to a large extent on efficient control of manufacturing processes to achieve predefined quality of the final product. In this paper, the authors review the various analytical methods that can enable use of PAT.

Pharmaceutical Technology
pp. s16-s22, s28-s31


1. FDA, PAT Guidance for Industry— A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance, September, (2004).

2. E.K. Read et al., Biotechnol. Bioengin. 105, 276–284 (2010).

3. E.K. Read et al, Biotechnol. Bioengin. 105, 285–295 (2010).

4. A.S. Rathore and H. Winkle, Nat. Biotechnol. 27, 26–34 (2009).

5. A.S. Rathore, R. Bhambure, and V. Ghare, Anal. Bioanal. Chem. 398, 137–154 (2010).

6. W.F. McClure et al., Near-Infrared Technology in the Agricultural and Food Industries, 2, 145–169 (2001).

7. Handbook of Near-Infrared Analysis, D.A. Burns and E.W. Ciurczak, Eds. (CRC Press, Taylor & Francis Group, Boca Raton, Florida, 2001) 22, 573–575.

8. M. Roman Balabin, Z. Ravilya Safieva, and I. Ekaterina Lomakina, Chemometr. Intell. Lab 2, 183–188 (2007).

9. A.O. Kirdar, G. Chen, and A.S. Rathore, Biotechnol. Prog. 26, 527–531 (2010).

10. S. Gnoth, M. Jenzsch, R. Simutis, and A. Lubbert, J. Biotechnol. 132, 180–186 (2007).

11. X. Lawrence Yu et al, Advan. Drug Del. Rev. 56, 349–369 (2004).

12. C. Dirk Hinz, Anal. and Bioanal. Chem. 384, 1036–1042 (2006).

13. P.J. Treado and M.D. Morris, Prac. Spectros. Series 16, (1993).

14. P. Matousek and A.W. Parker, Raman Spectrosc. 38, 563–567 (2007).

15. T.R.M. De Beer et al., Anal. Chem. 79, 7992–8003 (2007).


17. I. Duarte et al., Agric. Food Chem. 50, 2475–2481 (2002).

18. C. Goudar et al., Metabolic Engin. 12, 138–149 (2010).

19. H. Metz and K. Mader, Inter. J. of Pharmaceutics 364, 170–175 (2008).

20. E. Heinzle and A. Oeggerli., Anal. Chim. Acta. 238, 101–115 (1990).

21. S. Chauvatcharins et al. Bioeng. 79, 264–269 (1995).

22. D. Smith and P. Španlm, Mass Spectrom. Rev. 24, 661–700, (2005).

23. F. Erni, J. of Chrom. 251, 141–151 (1982).

24. E.P.C. Lai, B.L.C., and S. Chen, App. Spec. 42, 381–529 (1988).

25. J. Medendorp and R.A. Lodder, PharmSciTech 7, 175–183 (2006).

26. G. Robert Buice, Jr., P. Pinkston, and A. Robert, Soc. for App. Spec. 48, 517–524 (1994).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here